세계의 마이크로일렉트로닉스 의료용 임플란트 시장 : 제품, 기술 및 지역별(2024-2031년)

Microelectronic Medical Implants Market

Valuation - 2024-2031

The growing demand for microelectronic medical implants. The aging population is rapidly increasing, resulting in a rising prevalence of chronic diseases like heart disease, diabetes, and neurological disorders. Implantable devices are frequently used to treat symptoms and improve the quality of life for several diseases. the market size surpass USD 29.89 Billion valued in 2024 to reach a valuation of aroundUSD 50.21 Billion by 2031.

Technological advancements have made it possible to create smaller, more sophisticated implants with increased functionality and reliability. This has broadened the spectrum of uses for these devices, making them more appropriate for a larger patient population. The increased knowledge of the benefits of minimally invasive procedures, as well as the availability of more inexpensive healthcare solutions, are driving up demand for microelectronic medical implants. The rising demand for cost-effective and efficient microelectronic medical implants is enabling the market grow at aCAGR of 6.70% from 2024 to 2031.

Microelectronic Medical Implants Market: Definition/ Overview

Microelectronic medical implants are advanced devices that incorporate microelectronics technology into medical procedures. These implants are placed in the human body to monitor, diagnose, and treat a number of medical diseases. Pacemakers, cochlear implants, neurostimulators, and drug-delivery devices are some examples. Using micro-scale components, these devices work with accuracy, allowing for long-term health monitoring and intervention. They are used in a variety of medical sectors, including cardiology, neurology, and orthopedics, where they serve an important role in treating chronic diseases, increasing patient mobility, and recovering lost sensory functions.

Advances in nanotechnology, wireless connectivity, and biocompatible materials point to a bright future for microelectronic medical implants. Emerging developments, such as brain-computer interfaces and smart implants, have the potential to transform personalized medicine and improve treatment outcomes for disorders like epilepsy, Parkinson's disease, and paralysis.

The rising frequency of chronic diseases and an aging population will drive demand for these implants, while advances in reduction, battery life, and data integration will expand their applicability to new medical sectors. This technology is projected to have a big impact on the future of healthcare by providing more complex, minimally intrusive patient care options.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How will the Increasing Prevalence of Cardiovascular Diseases Drive the Microelectronic Medical Implants Market?

The increasing prevalence of cardiovascular diseases is propelling the microelectronic medical implants market. As cardiovascular diseases continue to be the largest cause of mortality in the world, killing around 17.9 million people each year, the need for devices such as pacemakers and implantable cardioverter-defibrillators (ICDs) grows. With about 2.7 million people in the United States suffering from atrial fibrillation, which is frequently treated with pacemakers, the rising prevalence of heart-related illnesses emphasizes the need for these life-saving implants, driving market expansion.

The growing geriatric population is boosting the microelectronic medical implant industry. As the world's population ages, with the number of persons aged 65 and older expected to climb from 9% in 2019 to 16% by 2050, there is an increasing demand for implants to treat age-related illnesses. In Europe and North America, where one in every four individuals will be beyond the age of 65 by 2050, demand for microelectronic implants to treat chronic diseases and age-related health conditions is predicted to rise.

How Does the Surgical Risks Affect the Growth of the Microelectronic Medical Implants Market?

Surgical risks can impede the growth of the microelectronic medical implants market. Implant treatments have potential consequences such as infections, device malfunction, and body rejection, which may prevent patients and healthcare providers from using these devices. The invasive nature of the surgeries and the associated recovery time may create concerns, restricting the use of microelectronic implants. These risks hinder market expansion by influencing patient and provider choices.

High costs will affect the expansion of the microelectronic medical implants market. These devices, which include pacemakers and neurostimulators, frequently cost significant costs for manufacturing, insertion, and continuing maintenance. Patients may struggle to adopt due to significant upfront fees and limited insurance coverage in certain countries. Healthcare providers in developing markets may struggle to provide these advanced therapies due to cost constraints, thereby slowing market expansion, particularly in lower-income regions.

Category-Wise Acumens

Will the Increasing Prevalence of Cardiovascular Diseases Fuel the Pacemakers & Defibrillators Segment for the Microelectronic Medical Implants Market?

Pacemakers and defibrillators have long held a leading position in the microelectronic medical implant market. The rising prevalence of cardiovascular disorders will propel the pacemakers and defibrillators segment of the microelectronic medical implants market. As arrhythmias and heart failure become increasingly widespread, so does the demand for life-saving technologies like pacemakers and implantable defibrillators. With cardiovascular disease being the leading cause of death globally, accounting for 17.9 million deaths per year according to the WHO, and conditions such as atrial fibrillation affecting millions, these devices are essential for managing and treating heart disorders, fueling the growth of this segment.

The increasing use of pacemakers and defibrillators to treat heart arrhythmias, particularly among the elderly, will fuel the expansion of this area of the microelectronic medical implants market. As the world's population ages, the prevalence of arrhythmias and other heart disorders rises, necessitating the usage of these devices for effective therapy. With an increasing older population prone to cardiovascular problems, demand for pacemakers and defibrillators is predicted to explode, propelling market expansion in this sector.

Does Remote Monitoring and Programming Boost the RF Technology Segment in the Microelectronic Medical Implants market?

RF Technology is emerging as the fastest-expanding segment in the microelectronic medical implant market. Remote monitoring and programming will propel the RF technology segment of the microelectronic medical implants market. As medical implants incorporate more wireless capabilities for remote monitoring and programming, the demand for improved RF technology rises. This technology enables real-time data transfer and device adjustments without the need for intrusive procedures, which improves patient care and convenience. Adopting RF technology is consequently essential to enhancing the functioning and efficiency of medical implants, thereby driving their market growth.

Reducing the demand for frequent surgical interventions will propel the RF technology segment of the microelectronic medical implants market. RF technology allows wireless communication for remote monitoring and programming of medical implants, reducing the need for invasive procedures and frequent surgeries. By allowing healthcare providers to make adjustments and monitor device performance remotely, RF technology improves patient comfort while reducing healthcare costs, increasing acceptance, and driving growth in this segment.

Country/Region-wise Acumens

Will the Strong Healthcare Infrastructure Lead the North American Region for the Microelectronic Medical Implants Market?

North America is the leading region in the microelectronic medical implant market. North America's microelectronic medical implant market will be driven by its robust healthcare infrastructure. The region's significant investment in healthcare, with US national health expenditure hitting USD 4.3 Trillion in 2021 and projected to reach USD 6.8 Trillion by 2031, encourages the use of modern medical technologies. Over 6,000 institutions in the United States are equipped with advanced procedures, and Canada's USD 308 Billion health expenditure in 2021 demonstrates its commitment to funding such breakthroughs. This solid base fuels the demand for sophisticated implants in the region.

Advanced research and development (R&D) will propel the microelectronic medical implants market in North America. The region's significant R&D investments, with US expenditures hitting USD 667 Billion in 2020 and expected to exceed USD 700 Billion by 2023, demonstrate a strong concentration on medical technology advancement. The FDA approved 132 innovative medical devices in 2021, a 39% increase over 2017, demonstrating significant innovation. The predicted growth of the global neurostimulation devices market from USD 7.6 Billion in 2022 to USD 13.3 Billion in 2027 demonstrates the significance of these breakthroughs. Furthermore, major R&D spending by the US semiconductor sector contributes to the development of advanced microelectronic implants.

Will the Manufacturing Hubs in the Asia Pacific Region Drive the Microelectronic Medical Implants Market?

Asia-Pacific is emerging as the fastest-growing region in the microelectronic medical implants market. Manufacturing hubs will fuel Asia-Pacific's microelectronic medical implant market. The region's supremacy in semiconductor manufacture, with the Asia-Pacific industry estimated to reach USD 395 Billion by 2022 and expand at a 10% CAGR, is critical for cost-effective implant production. China's medical device market, worth USD 137 Billion in 2021, and India's expected expansion to USD 50 Billion by 2025, aided by large government incentives, strengthen the region's manufacturing capabilities. These features, together with expanding healthcare requirements and chronic illness incidence, place the Asia-Pacific region at the leading edge of making microelectronic implants more accessible and inexpensive.

The Asia-Pacific region's huge and expanding population is driving the market for microelectronic medical implants. The region's 4.3 billion population is rapidly aging, with the number of individuals aged 60 and up anticipated to almost triple to 1.3 billion by 2050. This generational transition, combined with the high incidence of noncommunicable disorders including cardiovascular disease and diabetes, is driving strong demand for advanced medical implants. The market for implantable medical devices in the region is expected to rise from USD 23.1 Billion in 2023 to USD 32.1 Billion by 2028, indicating rising healthcare needs and the prevalence of chronic diseases.

Competitive Landscape

The microelectronic medical implants market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the microelectronic medical implants market include:

• Abbott Laboratories
• Medtronic plc
• Boston Scientific Corporation
• Zimmer Biomet
• Cochlear Limited
• LivaNova PLC
• Second Sight Medical Products, Inc.
• Nurotron Biotechnology Co. Ltd.
• Biotronik SE & Co. KG
• Nevro Corp
• Sonova Holding AG.

Latest Developments

• In February 2021, Medtronic gained FDA approval for their next-generation Micra pacemaker, the world's tiniest pacemaker. The device is intended to be implanted directly into the heart, providing a minimally invasive alternative to standard pacemakers.
• In August 2021, Abbott Laboratories announced that the FDA has approved their Infinity DBS system, which is a deep brain stimulation device used to treat Parkinson's disease and essential tremors. The gadget incorporates modern stimulation technology that enables individualized therapy and real-time patient feedback.
• In September 2021, LivaNova announced the debut of its next-generation Vagus Nerve Stimulation (VNS) therapeutic device for epilepsy. The system uses advanced simulation technology to provide patients with a tailored approach to therapy.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL MICROELECTRONIC MEDICAL IMPLANTS MARKET

• 1.1 OVERVIEW OF THE MARKET
• 1.2 SCOPE OF REPORT
• 1.3 ASSUMPTIONS

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 DATA MINING
• 3.2 VALIDATION
• 3.3 PRIMARY INTERVIEWS
• 3.4 LIST OF DATA SOURCES

4 GLOBAL MICROELECTRONIC MEDICAL IMPLANTS MARKET OUTLOOK

• 4.1 OVERVIEW
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
  • 4.2.2 RESTRAINTS
  • 4.2.3 OPPORTUNITIES
• 4.3 PORTERS FIVE FORCE MODEL
• 4.4 VALUE CHAIN ANALYSIS

5 GLOBAL MICROELECTRONIC MEDICAL IMPLANTS MARKET, BY TECHNOLOGIES

• 5.1 OVERVIEW
• 5.2 RF TECHNOLOGIES
• 5.3 SENSORS
• 5.4 OTHERS

6 GLOBAL MICROELECTRONIC MEDICAL IMPLANTS MARKET, BY PRODUCT

• 6.1 OVERVIEW
• 6.2 PACEMAKERS AND DEFIBRILLATORS
• 6.3 NEUROSTIMULATOR
• 6.4 IMPLANTABLE DRUG PUMPS
• 6.5 COCHLEAR IMPLANTS
• 6.6 OCULAR IMPLANTS
• 6.7 RETINAL IMPLANTS
• 6.8 OTHERS

7 GLOBAL MICROELECTRONIC MEDICAL IMPLANTS MARKET, BY GEOGRAPHY

• 7.1 OVERVIEW
• 7.2 NORTH AMERICA
  • 7.2.1 U.S.
  • 7.2.2 CANADA
  • 7.2.3 MEXICO
• 7.3 EUROPE
  • 7.3.1 GERMANY
  • 7.3.2 U.K.
  • 7.3.3 FRANCE
  • 7.3.4 REST OF EUROPE
• 7.4 ASIA PACIFIC
  • 7.4.1 CHINA
  • 7.4.2 JAPAN
  • 7.4.3 INDIA
  • 7.4.4 REST OF ASIA PACIFIC
• 7.5 REST OF THE WORLD
  • 7.5.1 LATIN AMERICA
  • 7.5.2 MIDDLE EAST AND AFRICA

8 GLOBAL MICROELECTRONIC MEDICAL IMPLANTS MARKET COMPETITIVE LANDSCAPE

• 8.1 OVERVIEW
• 8.2 COMPANY MARKET RANKING
• 8.3 KEY DEVELOPMENT STRATEGIES

9 COMPANY PROFILES

• 9.1 ABBOTT LABORATORIES
  • 9.1.1 OVERVIEW
  • 9.1.2 FINANCIAL PERFORMANCE
  • 9.1.3 PRODUCT OUTLOOK
  • 9.1.4 KEY DEVELOPMENTS
• 9.2 MEDTRONIC PLC
  • 9.2.1 OVERVIEW
  • 9.2.2 FINANCIAL PERFORMANCE
  • 9.2.3 PRODUCT OUTLOOK
  • 9.2.4 KEY DEVELOPMENTS
• 9.3 BOSTON SCIENTIFIC CORPORATION
  • 9.3.1 OVERVIEW
  • 9.3.2 FINANCIAL PERFORMANCE
  • 9.3.3 PRODUCT OUTLOOK
  • 9.3.4 KEY DEVELOPMENTS
• 9.4 ZIMMER BIOMET
  • 9.4.1 OVERVIEW
  • 9.4.2 FINANCIAL PERFORMANCE
  • 9.4.3 PRODUCT OUTLOOK
  • 9.4.4 KEY DEVELOPMENTS
• 9.5 COCHLEAR LIMITED
  • 9.5.1 OVERVIEW
  • 9.5.2 FINANCIAL PERFORMANCE
  • 9.5.3 PRODUCT OUTLOOK
  • 9.5.4 KEY DEVELOPMENTS
• 9.6 LIVANOVA PLC
  • 9.6.1 OVERVIEW
  • 9.6.2 FINANCIAL PERFORMANCE
  • 9.6.3 PRODUCT OUTLOOK
  • 9.6.4 KEY DEVELOPMENTS
• 9.7 SECOND SIGHT MEDICAL PRODUCTS, INC.
  • 9.7.1 OVERVIEW
  • 9.7.2 FINANCIAL PERFORMANCE
  • 9.7.3 PRODUCT OUTLOOK
  • 9.7.4 KEY DEVELOPMENTS
• 9.8 NUROTRON BIOTECHNOLOGY CO. LTD.
  • 9.8.1 OVERVIEW
  • 9.8.2 FINANCIAL PERFORMANCE
  • 9.8.3 PRODUCT OUTLOOK
  • 9.8.4 KEY DEVELOPMENTS
• 9.9 BIOTRONIK SE & CO. KG
  • 9.9.1 OVERVIEW
  • 9.9.2 FINANCIAL PERFORMANCE
  • 9.9.3 PRODUCT OUTLOOK
  • 9.9.4 KEY DEVELOPMENTS
• 9.10 NEVRO CORP
  • 9.10.1 OVERVIEW
  • 9.10.2 FINANCIAL PERFORMANCE
  • 9.10.3 PRODUCT OUTLOOK
  • 9.10.4 KEY DEVELOPMENTS

10 KEY DEVELOPMENTS

• 10.1 PRODUCT LAUNCHES/DEVELOPMENTS
• 10.2 MERGERS AND ACQUISITIONS
• 10.3 BUSINESS EXPANSIONS
• 10.4 PARTNERSHIPS AND COLLABORATIONS

11 APPENDIX

• 11.1 RELATED RESEARCH